Pharmacological reports : PR · 2026
preSCRIPT: Large-scale prescription search and annotation engine for pharmacogenomic studies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pieczarka Maria, Pieńkowski Paweł, Konowalska Paula, Grubarek Sylwia, Hajto Jacek, Hoinkis Dżesika, Piechota Marcin, Borczyk Małgorzata, Korostyński Michał
Аннотация
BACKGROUND: Pharmacogenetics (PGx) has traditionally focused on a small number of high-impact variants affecting drug response due to the fact that PGx studies are labor-intensive and therefore low-throughput. Population biobanks linked to electronic health records (EHRs), including the UK Biobank (UKB) with prescription data for ~ 230,000 individuals offer opportunities to scale PGx research. This, however, comes with a challenge as EHRs do not provide direct treatment response outcomes. One way to overcome this is to draw indirect drug response phenotypes from prescription records.
METHODS: Here, we propose preSCRIPT, a framework to filter and annotate raw prescriptions from the UKB to derive phenotypes for analyses which includes an algorithm to distinguish short prescription gaps from true dose changes. As a proof of concept, we applied preSCRIPT to warfarin, paracetamol, codeine, amitriptyline, simvastatin, aspirin, and amlodipine and derived therapy length and median daily doses. We tested associations for those seven drugs and two phenotypes across single-nucleotide polymorphisms (SNPs), cytochrome P450 (CYP) genes, and human leukocyte antigen (HLA) alleles.
RESULTS: We recovered known associations such as CYP2D6 variants with amitriptyline therapy length and dose, CYP2C9/CYP4F2/CYP2C19 with warfarin dose, and CYP2D6 with codeine dose. For drugs without formal PGx guidelines, we identified an association between CYP2D6 enzyme activity and aspirin therapy length and several SNPs, including rs62471929 (CYP3A5), a variant for amlodipine dose, which reached nominal significance in an independent hold-out set.
CONCLUSIONS: Overall, preSCRIPT provides a scalable framework for prescription-based discovery in pharmacogenomics. As a proof of concept it recovers established PGx associations and nominates novel, hypothesis-generating candidate loci.
METHODS: Here, we propose preSCRIPT, a framework to filter and annotate raw prescriptions from the UKB to derive phenotypes for analyses which includes an algorithm to distinguish short prescription gaps from true dose changes. As a proof of concept, we applied preSCRIPT to warfarin, paracetamol, codeine, amitriptyline, simvastatin, aspirin, and amlodipine and derived therapy length and median daily doses. We tested associations for those seven drugs and two phenotypes across single-nucleotide polymorphisms (SNPs), cytochrome P450 (CYP) genes, and human leukocyte antigen (HLA) alleles.
RESULTS: We recovered known associations such as CYP2D6 variants with amitriptyline therapy length and dose, CYP2C9/CYP4F2/CYP2C19 with warfarin dose, and CYP2D6 with codeine dose. For drugs without formal PGx guidelines, we identified an association between CYP2D6 enzyme activity and aspirin therapy length and several SNPs, including rs62471929 (CYP3A5), a variant for amlodipine dose, which reached nominal significance in an independent hold-out set.
CONCLUSIONS: Overall, preSCRIPT provides a scalable framework for prescription-based discovery in pharmacogenomics. As a proof of concept it recovers established PGx associations and nominates novel, hypothesis-generating candidate loci.